Researchers evaluated the safety and efficacy of teriparatide for the treatment of severe osteoporosis in patients with Duchenne muscular dystrophy.
Factors during gestation and infancy may impact bone health in young adulthood.
Bone microarchitecture and strength are reduced in women living with HIV, and tenofovir treatment may contribute to bone deficits.
Lower physical function and lean body mass are associated with increased risk for accelerated bone loss in older patients with previous hip fracture.
Abaloparatide treatment significantly increases bone mineral density in younger postmenopausal women at high risk for fracture.
Researchers assessed the association between serum uric acid levels and osteoporosis risk in postmenopausal women with rheumatoid arthritis.
Researchers evaluated the effects of follow-up therapy after denosumab discontinuation on bone resorption, bone mineral density, and clinical fracture risk.
The FDA has approved Crysvita for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in patients aged ≥2 years.
Researchers assessed the impact of primary hand osteoarthritis on bone mass, microstructure, and biomechanics in the affected skeletal regions.
Individuals with diabetes have an increased risk for hip and nonvertebral fractures.
